Deals In Depth: May 2017
Executive Summary
AstraZeneca could pay up to $2.1 billion in an Anticalin protein therapeutics deal with Pieris, centered around respiratory diseases. In the latest CRO takeover, Thermo Fisher Scientific bought Patheon for $7.2 billion. Biopharma financing declined in May compared with April, mostly due to a decrease in public offering value.
You may also be interested in...
The Biopharma A List: Taking The Pulse Of Newco Creation
On the new company creation front, using Series A financings as a proxy, start-ups have not escaped the challenging funding environment. Here we update trends in those first-time rounds for 2023.
CGT Development Is Booming, But Manufacturing Workforce Must Keep Up
Due to the unprecedented growth in the development of cell and gene therapies over the past decade, there is now high demand for certain workforce roles, especially in highly specialized areas and entry-level manufacturing positions.
RNA Medicines: Advancements Leading To Investments
Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.